Abstract
This year, as many as 1.5 million Americans may experience a heart attack and, according to the American Heart Association, approximately one third of them will die as a result. Despite a recent decline in the number of fatalities attributed to cardiovascular diseases, they are still considered to be the most widespread cause of death in this country. In addition to the cost in human lives, the economic cost of cardiovascular disease will exceed $72 billion in 1985, the association predicts. The following reports from the American Heart Association's Science Writers' Forum, held earlier this year in Monterey, Calif, summarize some of the recent developments in cardiovascular research. Clinical investigations continue on the efficacy and safety of a compact, programmable, transvenous cardioversion device at Indiana University School of Medicine, Indianapolis ( JAMA [MEDICAL NEWS] 1983; 250:1809-1811). Douglas P. Zipes, MD, professor of medicine and one of the developers of the experimental
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
